In conclusion, we showed that MYEOV suppression is a new mechanism that contributes to a poor prognosis in pancreatic cancer patients through the activation of the folate cycle and the c-Myc and mTORC1 pathways (Fig. 6). This evidence concerns the gene MYEOV and pancreatic neoplasm.